The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Theravance Biopharma Inc (NASDAQ: TBPH) closed the day trading at $12.42 up 4.19% from the previous closing price of $11.92. In other words, the price has increased by $4.19 from its previous closing price. On the day, 0.65 million shares were traded. TBPH stock price reached its highest trading level at $12.67 during the session, while it also had its lowest trading level at $11.921.
Ratios:
For a better understanding of TBPH, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.83 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.24. For the most recent quarter (mrq), Quick Ratio is recorded 4.77 and its Current Ratio is at 6.70. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on August 06, 2024, Downgraded its rating to Market Perform and sets its target price to $10 from $15 previously.
On April 12, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $21.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 14 ’25 when Farnum Rhonda sold 10,000 shares for $11.39 per share. The transaction valued at 113,870 led to the insider holds 326,918 shares of the business.
RHONDA FARNUM bought 10,000 shares of TBPH for $113,869 on Jul 14 ’25. On Jun 02 ’25, another insider, Farnum Rhonda, who serves as the SVP, COMM & MEDICAL AFFAIRS of the company, sold 24,000 shares for $11.00 each. As a result, the insider received 264,000 and left with 336,918 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TBPH now has a Market Capitalization of 621016128 and an Enterprise Value of 513316864. As of this moment, Theravance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 53.33, and their Forward P/E ratio for the next fiscal year is 40.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.92. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.04 while its Price-to-Book (P/B) ratio in mrq is 3.74. Its current Enterprise Value per Revenue stands at 7.865 whereas that against EBITDA is -11.674.
Stock Price History:
The Beta on a monthly basis for TBPH is 0.03, which has changed by 0.50545454 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, TBPH has reached a high of $11.99, while it has fallen to a 52-week low of $7.88. The 50-Day Moving Average of the stock is 11.72%, while the 200-Day Moving Average is calculated to be 27.25%.
Shares Statistics:
Over the past 3-months, TBPH traded about 263.60K shares per day on average, while over the past 10 days, TBPH traded about 333760 shares per day. A total of 50.00M shares are outstanding, with a floating share count of 45.91M. Insiders hold about 8.19% of the company’s shares, while institutions hold 91.95% stake in the company. Shares short for TBPH as of 1753920000 were 4123585 with a Short Ratio of 15.64, compared to 1751241600 on 4162817. Therefore, it implies a Short% of Shares Outstanding of 4123585 and a Short% of Float of 13.36.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Theravance Biopharma Inc (TBPH) is currently in the spotlight, with 3.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.15, with high estimates of $0.46 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.15 and -$0.32 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is -$0.41, with 3.0 analysts recommending between -$0.2 and -$0.65.
Revenue Estimates
5 analysts predict $19.05M in revenue for the current quarter. It ranges from a high estimate of $23.7M to a low estimate of $17M. As of the current estimate, Theravance Biopharma Inc’s year-ago sales were $16.87MFor the next quarter, 5 analysts are estimating revenue of $46.51M. There is a high estimate of $95.73M for the next quarter, whereas the lowest estimate is $19.1M.
A total of 5 analysts have provided revenue estimates for TBPH’s current fiscal year. The highest revenue estimate was $156.07M, while the lowest revenue estimate was $95.5M, resulting in an average revenue estimate of $115.21M. In the same quarter a year ago, actual revenue was $64.38MBased on 5 analysts’ estimates, the company’s revenue will be $118.32M in the next fiscal year. The high estimate is $178.21M and the low estimate is $72.4M.
